

# Optimising the management of mental health problems in primary care

<b>Submission date</b> 13/01/2020	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 22/01/2020	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 24/02/2021	<b>Condition category</b> Mental and Behavioural Disorders	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English Summary

### Background and study aims

Depression and anxiety are common problems and a major cause of disability in the UK. Most people with these conditions are managed in primary care and will be offered a variety of options depending on the severity of symptoms, local service availability and personal preference.

This study will evaluate the effectiveness of a new treatment pathway designed to optimise the patient experience without increasing the cost burden. It uses new technologies to help patients identify and engage with support, manage symptoms and monitor response.

### Who can participate?

Patients aged 18 years or older who attend the nurse-led mental health clinic at the trial centre.

### What does the study involve?

Participants who are eligible and agree to take part will have their details registered on the I-spero system which will assist the clinician in identifying the most appropriate management option for their condition. Treatment will continue as usual for eight weeks, at which time participants will be asked to complete a satisfaction questionnaire.

### What are the possible benefits and risks of participating?

Benefits include the chance to use new technology before widely available. No risks.

### Where is the study run from?

The University of Nottingham Health Service, UK

### When is the study starting and how long is it expected to run for?

January 2020 to August 2020 (updated 24/02/2021, previously: June 2020)

### Who is funding the study?

1. The Microcurrent Site Limited, UK
2. P1vital Products Limited, UK
3. National Institute for Health Research (NIHR), UK

Who is the main contact?  
Dr Simon Royal  
ncccg.research@nhs.net

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Simon Royal

**ORCID ID**  
<http://orcid.org/0000-0002-4560-6036>

**Contact details**  
Cripps Health Centre  
University Park  
Nottingham  
United Kingdom  
NG7 2QW  
+44 (0)1158468888  
ncccg.research@nhs.net

## Additional identifiers

**EudraCT/CTIS number**  
Nil known

**IRAS number**  
271778

**ClinicalTrials.gov number**  
Nil known

**Secondary identifying numbers**  
CPMS 44191, IRAS 271778

## Study information

**Scientific Title**  
Optimising the effectiveness of the management of mental health problems in primary care using new technologies

**Study hypothesis**  
The optimised pathway improves the management of mental health problems in primary care

**Ethics approval required**  
Old ethics approval format

**Ethics approval(s)**

Approved 10/12/2019, NHS Wales REC 6, (Health and Care Research Wales Support and Delivery Centre, Castlebridge 4, 15-19 Cowbridge Road East, Cardiff, CF11 9AB; +44 (0)1874 615949; Wales.REC6@wales.nhs.uk), ref: 19/WA/0344

**Study design**

Interventional non-randomized study

**Primary study design**

Interventional

**Secondary study design**

Non randomised study

**Study setting(s)**

Hospital

**Study type(s)**

Treatment

**Participant information sheet**

Not available in web format, please use the contact details below to request a patient information sheet

**Condition**

Mood [affective] disorders, Neurotic, stress-related and somatoform disorders

**Interventions**

Entry into the study will be offered to attendees at a nurse-led clinic for people who have mental health problems which will be set up in Nottingham, UK. The clinic will run at the student health centre on the University of Nottingham main campus. All attendees will be assessed by a trained mental health nurse on presentation to the service. Those eligible to participate must be registered with the practice, must be aged 18 or over, must have capacity to understand the patient information sheet and give consent to participation and must not require immediate referral to secondary care because of symptom severity. Patients not meeting these criteria will be offered usual care according to the standard operating procedures of the service. Patients who are eligible to join the study will be given an information sheet and time to consider participation. Those who do not give consent will be offered usual care according to the standard operating procedures of the service. Those who consent will be entered into the trial.

The first study procedure will be registration with the ispero system (CE-marked but not currently part of standard management) and completion of the baseline assessments it contains. The results of this will be available immediately and will assist the clinician in identifying the most appropriate management option. This could be one or more of the following:

- self help
- support agencies including NHS, University and voluntary sector
- psychological therapy with one of the three NHS provider organisations in Nottingham
- Alpha-Stim treatment for those with generalized anxiety (CE-marked but not currently standard management)
- referral to a GP to discuss medication

The participants' response to these options will be monitored by ispero and used at future contacts to guide further management.

There will be no planned study visits but participants will be seen by the appropriate clinician at intervals agreed at the end of each contact.

Eight weeks after recruitment an investigator will contact the participant and ask permission to inspect their I-spero data and collect outcome measures. They will be offered an opportunity to withdraw consent for participation at this point. They will also be offered a personal appointment with a study clinician so that data can be reviewed in a consultation environment. They will also be asked to complete a short satisfaction survey.

A control group of patients attending their GP practice with mental health problems that would have been eligible for inclusion in the study will be identified at the end of the study and a retrospective notes review will be performed by the investigator as part of routine service evaluation. It will be possible to compare some of the baseline and eight week outcome measures as this information is collected as part of standard practice.

Any data extracted for comparison will be fully anonymised and no patient identifiable data will be seen by any person who is not an employee of the study practice.

The null hypothesis will be that the new pathway is no more effective or acceptable than standard treatment. This design has been chosen as it aligns with current NHS priorities and causes minimal disruption to participants and local services. We considered a randomised controlled design but felt that this would cause ethical and logistical problems that would not outweigh the benefits in outcome data quality and comparability.

## **Intervention Type**

Device

## **Phase**

Not Applicable

## **Drug/device/biological/vaccine name(s)**

Alpha-Stim

## **Primary outcome measure**

Improvements from baseline to 8-weeks in I-spero data (I-spero uses a number of validated tests and an AI algorithm to monitor response to treatment)

## **Secondary outcome measures**

Satisfaction as measured by questionnaire at 8 weeks

## **Overall study start date**

01/08/2019

## **Overall study end date**

01/08/2020

## **Eligibility**

**Participant inclusion criteria**

1. Attendance at nurse-led mental health clinic
2. Registered with participating general practice (this is necessary to ensure that clinical alerts generated by the ispero system can be acted upon in a timely manner)
3. Capacity to understand information sheet and provide informed consent

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Both

**Target number of participants**

Planned Sample Size: 100; UK Sample Size: 100

**Total final enrolment**

55

**Participant exclusion criteria**

1. Patients not suitable for the nurse-led mental health clinic. These would include those who appear distressed or at acute risk of harm to themselves or others or who appear to be intoxicated. The reception staff at the practice are already skilled in identifying these patients. The nurse-led clinic would also not be suitable for those with mental health problems related to a terminal or acute physical illness.
2. Those unable to communicate effectively in English

**Recruitment start date**

01/02/2020

**Recruitment end date**

30/04/2020

**Locations****Countries of recruitment**

England

United Kingdom

**Study participating centre**

**The University of Nottingham Health Service**

Cripps Health Centre

University Park

Nottingham

United Kingdom

NG7 2QW

# Sponsor information

## Organisation

University of Nottingham

## Sponsor details

Cripps Health Centre  
Nottingham  
England  
United Kingdom  
NG7 2QW  
+44 (0)1158468888  
ncccg.research@nhs.net

## Sponsor type

University/education

## Website

<http://www.nottingham.ac.uk/>

## ROR

<https://ror.org/01ee9ar58>

## Organisation

P1vital Products Ltd

## Sponsor details

Manor House  
Howbery Business Park  
Wallingford  
Oxford  
United Kingdom  
OX10 8BA  
+44 (0)1865 522030  
info@p1vital.com

## Sponsor type

Industry

## Organisation

The MicroCurrent Site

**Sponsor details**

Unit 3, Brookside  
Sawtry  
Huntingdon  
United Kingdom  
PE28 5SB  
+44 (0)1487 208041  
info@themicrocurrentsite.co.uk

**Sponsor type**

Industry

**Funder(s)****Funder type**

Industry

**Funder Name**

The Microcurrent Site Limited

**Funder Name**

National Institute for Health Research (NIHR) (UK)

**Alternative Name(s)**

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

United Kingdom

**Funder Name**

P1 Vital Products Limited

**Results and Publications**

### Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal.

### Intention to publish date

31/03/2022

### Individual participant data (IPD) sharing plan

The current data sharing plans for this study are unknown and will be available at a later date.

### IPD sharing plan summary

Data sharing statement to be made available at a later date

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">HRA research summary</a>			28/06/2023	No	No